Charles River Laboratories International’s (CRL) Neutral Rating Reaffirmed at UBS Group

Charles River Laboratories International (NYSE:CRL)‘s stock had its “neutral” rating reiterated by UBS Group in a research report issued on Friday, Marketbeat Ratings reports. They currently have a $185.00 target price on the medical research company’s stock, down from their prior target price of $250.00. UBS Group’s price objective points to a potential upside of 12.97% from the company’s current price.

Several other brokerages also recently weighed in on CRL. Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their target price for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. Bank of America reduced their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Robert W. Baird reduced their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, September 20th. TD Cowen upped their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Finally, Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $209.00.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $163.77 on Friday. The company has a market cap of $8.37 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38. The firm’s fifty day moving average is $190.64 and its 200 day moving average is $198.42. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a 52-week low of $160.85 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the prior year, the firm posted $2.72 earnings per share. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. Sell-side analysts forecast that Charles River Laboratories International will post 10.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by company insiders.

Institutional Trading of Charles River Laboratories International

Institutional investors have recently modified their holdings of the company. Wolff Wiese Magana LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at about $32,000. Versant Capital Management Inc boosted its holdings in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. boosted its holdings in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at about $59,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).